Skip to content

Clinical trials

Breast Neoplasms trials in Italy

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Breast Neoplasms Country / region: Italy Clear all

809 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20008
20016
20027
200317
200414
200517
200624
200728
200828
200927
201016
201123
201226
201328
201439
201534
201620
201726
201844
201936
202038
202140
202245
202369
202451
202558
202620

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed361
Recruiting155
Unknown status108
Active, not recruiting96
Terminated62
Not yet recruiting11
Withdrawn8
Enrolling by invitation5
Approved for marketing3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Hoffmann-La Roche65
European Institute of Oncology53
Novartis Pharmaceuticals50
AstraZeneca37
Pfizer30
Eli Lilly and Company26
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano22
Fondazione Policlinico Universitario Agostino Gemelli IRCCS21
ETOP IBCSG Partners Foundation18
Consorzio Oncotech15

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Breast Neoplasms809
Neoplasm Metastasis61
Neoplasms56
Ovarian Neoplasms32
Triple Negative Breast Neoplasms30
Carcinoma, Non-Small-Cell Lung26
Lung Neoplasms26
Colorectal Neoplasms24
Head and Neck Neoplasms18
Melanoma17

Trials

Showing 1 to 25 of 809. Each trial links to its page on Pharma Observatory.

709 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.